Project Details


WSIS Prizes Contest 2019 Nominee

Home-based Empowered Living for Parkinson’s Disease Patients


Description

The HELP project has created two new
cutting-edge products that will lead to
a major breakthrough in the treatment
of Parkinson’s disease: a sensor that
detects Parkinson’s symptoms and an
intraoral device that provides a non-invasive
way of administering PD medication.
The sensor and intraoral devices
are connected to the platform by means
of a gateway application running on a
mobile phone. All developed products
were integrated in a system so that doctors
were able to monitor and control
Parkinson’s disease patients.
The HELP project has worked on a
cutting-edge drug delivery system that
greatly improves the quality of life of patients
wearing subcutaneous and duodenal
pumps, but also patients following
a very strict scheduled oral treatment.
Both products will be distributed as part
of the current PD treatment packages
provided by pharmaceutical companies.
In the case of the sensor, these companies
are very interested in including this
device in the product portfolio.

Project website

http://www.aal-europe.eu/projects/help/


Images

Action lines related to this project
  • AL C7. E-health 2019
Sustainable development goals related to this project
  • Goal 3: Good health and well-being

Global digital compact (GDC) objectives related to this project None

Coverage
  • Western Europe and North America

Status

Completed

Start date

June 2009

End date

2012


Target beneficiary group(s)
  • People with disabilities

WSIS values promotion

The HELP Project consortium is designing a Health Monitoring System specifically targeted for the needs of Parkinson Disease (PD) patients. Without treatment, PD progresses over 5–10 years to a rigid, a kinetic state in which patients are incapable of caring for themselves. Death frequently results from complications of immobility, including aspiration pneumonia or pulmonary embolism. The availability of effective pharmacological treatment has altered radically the prognosis of PD; in most cases, good functional mobility can be maintained for many years, and the life expectancy increased substantially. Primarily, therapies are aimed at minimizing symptoms and maximizing function and quality of life.


Entity name

Telefónica I+D

Entity country—type

Spain Private Sector

Entity website

http://www.tid.es/

Partners

AAL Programme, Tech Research Centre for Dependency UPC, Hospital Foundation ABAT, NEVET, Peh-Med, Telecom Italia, University of Palermo, HSG-IMIT, MSG